Table 1. Patients’ baseline characteristics.
| Characteristics | Total, n=271 |
|---|---|
| Age, median [IQR], years | 68 [62–74] |
| Sex, n (%) | |
| Male | 190 (70.1) |
| Female | 81 (29.9) |
| BMI, median (IQR), kg/m2 | 21.3 (18.9–23.6) |
| ECOG PS, median [IQR] | 1 [0–1] |
| Tumor site, n (%) | |
| Esophagogastric junction | 22 (8.1) |
| Stomach | 249 (91.9) |
| Histology, n (%) | |
| Intestinal | 83 (30.6) |
| Diffuse | 179 (66.1) |
| Indeterminable | 9 (3.3) |
| HER2 status, n (%) | |
| Positive | 17 (6.3) |
| Negative | 92 (33.9) |
| Unknown | 162 (59.8) |
| Ascites, n (%) | |
| Presence | 142 (52.4) |
| Absence | 124 (45.8) |
| Unknown | 5 (1.8) |
| Number of organs with metastases, median [IQR] | 2 [1–2] |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance status; HER2, human epidermal growth factor receptor type 2; IQR, interquartile range.